| Title |
Advances in Alzheimer’s Disease Drug Development
|
|---|---|
| Published in |
BMC Medicine, March 2015
|
| DOI | 10.1186/s12916-015-0297-4 |
| Pubmed ID | |
| Authors |
Michael S Rafii, Paul S Aisen |
| Abstract |
Alzheimer's disease (AD) is the foremost cause of dementia worldwide. Clinically, AD manifests as progressive memory impairment followed by a gradual decline in other cognitive abilities leading to complete functional dependency. Recent biomarker studies indicate that AD is characterized by a long asymptomatic phase, with the development of pathology occurring at least a decade prior to the onset of any symptoms. Current FDA-approved treatments target neurotransmitter abnormalities associated with the disease but do not affect what is believed to be the underlying etiology. In this review, we briefly discuss the most recent therapeutic strategies being employed in AD clinical trials, as well the scientific rationale with which they have been developed. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 40% |
| Spain | 1 | 10% |
| Unknown | 5 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 60% |
| Science communicators (journalists, bloggers, editors) | 2 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 2% |
| United Kingdom | 2 | 1% |
| India | 1 | <1% |
| Unknown | 158 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 32 | 19% |
| Student > Ph. D. Student | 25 | 15% |
| Student > Master | 23 | 14% |
| Researcher | 15 | 9% |
| Student > Postgraduate | 15 | 9% |
| Other | 26 | 16% |
| Unknown | 29 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 17% |
| Agricultural and Biological Sciences | 26 | 16% |
| Biochemistry, Genetics and Molecular Biology | 17 | 10% |
| Chemistry | 15 | 9% |
| Psychology | 13 | 8% |
| Other | 26 | 16% |
| Unknown | 40 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2023.
All research outputs
#2,019,323
of 24,279,062 outputs
Outputs from BMC Medicine
#1,361
of 3,728 outputs
Outputs of similar age
#26,270
of 267,584 outputs
Outputs of similar age from BMC Medicine
#34
of 80 outputs
Altmetric has tracked 24,279,062 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,728 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.1. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,584 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.